Loading provider…
Loading provider…
Pulmonary Disease Physician in North Haven, CT
NPI: 1336234947Primary Employer
Yale Medicine
yalemedicine.org
HQ Phone
Get MD Danielle's Phone Numberphone_androidMobile
Get MD Danielle's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCT State Medical License
CT State Medical License
2006 - 2025
PA State Medical License
2000 - 2006

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Critical Care Medicine

American Board of Internal Medicine
Pulmonary Disease
Perelman School of Medicine - Philadelphia
med.upenn.edu
Medical School
Until 1999
University of Pennsylvania Health System
Fellowship • Pulmonary Disease and Critical Care Medicine
2002 - 2006
Residency • Internal Medicine
1999 - 2002
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 94729Measurement of lung diffusing capacity | 108 | 147 |
| 2 | 94727Test to determine lung volumes using gas dilution or washout | 106 | 141 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 88 | 140 |
| 4 | 94375Test to measure rate of airflow | 86 | 93 |
| 5 | 94618Test for exercise-induced lung stress | 60 | 76 |
Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Authors: Jeffrey Golden, Zeenat Safdar, Gordon Yung
Journal: Eur Respir J
Publication Date: 2013-05-16
Authors: Brian Bartholmai, Ganesh Raghu, Lawrence Ho
Journal: JAMA
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial
Authors: Jeffrey Golden, Lawrence Ho
Publication Date: 2018-06
Lead Sponsor: Hoffmann-La Roche
Intervention / Treatment: DRUG: PRM-151 (Zinpentraxin Alfa)
Lead Sponsor: Hoffmann-La Roche
Intervention / Treatment: DRUG: Placebo, DRUG: PRM-151 (Zinpentraxin Alfa)
Lead Sponsor: National Jewish Health
Collaborators: AstraZeneca, Yale University, National Center for Advancing Translational Sciences (NCATS), Icahn School of Medicine at Mount Sinai, Baylor University, International Center for Health Outcomes and Innovation Research
Intervention / Treatment: DRUG: Placebo, DRUG: Saracatinab